Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC
Clinical trial NCT06532591 · RECRUITING
Trial details
- NCT number
- NCT06532591
- Sponsor
- Sichuan Cancer Hospital and Research Institute
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-01
- Primary completion
- 2025-04-30
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.